A hazai kísérleti daganatkemoterápiai kutatások gyökerei és eredményei

Translated title of the contribution: Roots and results of experimental cancer chemotherapy in Hungary

A. Jeney, Kralovánszky Judit

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cancer chemotherapy represents a major area of oncology in Hungary, as the scientific contributions of the well trained and equipped research team are well known in many cancer centers abroad. The roots of the current research could be traced in the 1930s at the Internal Clinical Department of the Pázmány Peter University where the biological effects of mustard gas was investigated. The aims of these research were realized in 1950s at first in the National Institute of Oncology and later in other institutes as well. Consequently a multidisciplinary network of experimental cancer research involving pathologists, pharmacologists, biochemists, chemists and clinical doctors has been established in Hungary. Surveying the history of anticancer research with ample tradition makes possible to review the valuable achievements and to focus on experience to be utilized in the future. At the first stage of these studies the basic aim was to introduce new cytotoxic agents. One of these drugs, dibromomannitol is currently used in CML therapy and in the conditioning treatment before bone-marrow transplantation, whereas the other drug dibromodulcitol is under licensing for the treatment of brain tumours in USA. The introduction of updated pharmacokinetic and pharmacobiochemical research facilities had to be outlined in the second period of cancer chemotherapeutic studies as it was required by the drug development program. These new elements in cancer research allowed to elucidate the mode of actions of the cytostatic agents. Currently ongoing research differs in both conceptually and methodologically from the ones at previous periods. The aims of these studies concentrate on two tasks: 1.) To determine the pharmacobiochemical determinants of drugs action in human tumours for the prediction of drug responses. 2.) To modify the abnormal gene-expression underlying the malignant phenotype.

Original languageHungarian
Pages (from-to)75-84
Number of pages10
JournalMagyar Onkologia
Volume41
Issue number2
Publication statusPublished - 1997

Fingerprint

Hungary
Drug Therapy
Research
Neoplasms
Pharmaceutical Preparations
Mitobronitol
Mitolactol
Mustard Gas
Second Primary Neoplasms
Behavior Therapy
Cytotoxins
Cytostatic Agents
Licensure
Bone Marrow Transplantation
Brain Neoplasms
Pharmacokinetics
History
Phenotype
Gene Expression
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

A hazai kísérleti daganatkemoterápiai kutatások gyökerei és eredményei. / Jeney, A.; Judit, Kralovánszky.

In: Magyar Onkologia, Vol. 41, No. 2, 1997, p. 75-84.

Research output: Contribution to journalArticle

Jeney, A. ; Judit, Kralovánszky. / A hazai kísérleti daganatkemoterápiai kutatások gyökerei és eredményei. In: Magyar Onkologia. 1997 ; Vol. 41, No. 2. pp. 75-84.
@article{1da61a95dbc74313948b2d1228f79df0,
title = "A hazai k{\'i}s{\'e}rleti daganatkemoter{\'a}piai kutat{\'a}sok gy{\"o}kerei {\'e}s eredm{\'e}nyei",
abstract = "Cancer chemotherapy represents a major area of oncology in Hungary, as the scientific contributions of the well trained and equipped research team are well known in many cancer centers abroad. The roots of the current research could be traced in the 1930s at the Internal Clinical Department of the P{\'a}zm{\'a}ny Peter University where the biological effects of mustard gas was investigated. The aims of these research were realized in 1950s at first in the National Institute of Oncology and later in other institutes as well. Consequently a multidisciplinary network of experimental cancer research involving pathologists, pharmacologists, biochemists, chemists and clinical doctors has been established in Hungary. Surveying the history of anticancer research with ample tradition makes possible to review the valuable achievements and to focus on experience to be utilized in the future. At the first stage of these studies the basic aim was to introduce new cytotoxic agents. One of these drugs, dibromomannitol is currently used in CML therapy and in the conditioning treatment before bone-marrow transplantation, whereas the other drug dibromodulcitol is under licensing for the treatment of brain tumours in USA. The introduction of updated pharmacokinetic and pharmacobiochemical research facilities had to be outlined in the second period of cancer chemotherapeutic studies as it was required by the drug development program. These new elements in cancer research allowed to elucidate the mode of actions of the cytostatic agents. Currently ongoing research differs in both conceptually and methodologically from the ones at previous periods. The aims of these studies concentrate on two tasks: 1.) To determine the pharmacobiochemical determinants of drugs action in human tumours for the prediction of drug responses. 2.) To modify the abnormal gene-expression underlying the malignant phenotype.",
author = "A. Jeney and Kralov{\'a}nszky Judit",
year = "1997",
language = "Hungarian",
volume = "41",
pages = "75--84",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - A hazai kísérleti daganatkemoterápiai kutatások gyökerei és eredményei

AU - Jeney, A.

AU - Judit, Kralovánszky

PY - 1997

Y1 - 1997

N2 - Cancer chemotherapy represents a major area of oncology in Hungary, as the scientific contributions of the well trained and equipped research team are well known in many cancer centers abroad. The roots of the current research could be traced in the 1930s at the Internal Clinical Department of the Pázmány Peter University where the biological effects of mustard gas was investigated. The aims of these research were realized in 1950s at first in the National Institute of Oncology and later in other institutes as well. Consequently a multidisciplinary network of experimental cancer research involving pathologists, pharmacologists, biochemists, chemists and clinical doctors has been established in Hungary. Surveying the history of anticancer research with ample tradition makes possible to review the valuable achievements and to focus on experience to be utilized in the future. At the first stage of these studies the basic aim was to introduce new cytotoxic agents. One of these drugs, dibromomannitol is currently used in CML therapy and in the conditioning treatment before bone-marrow transplantation, whereas the other drug dibromodulcitol is under licensing for the treatment of brain tumours in USA. The introduction of updated pharmacokinetic and pharmacobiochemical research facilities had to be outlined in the second period of cancer chemotherapeutic studies as it was required by the drug development program. These new elements in cancer research allowed to elucidate the mode of actions of the cytostatic agents. Currently ongoing research differs in both conceptually and methodologically from the ones at previous periods. The aims of these studies concentrate on two tasks: 1.) To determine the pharmacobiochemical determinants of drugs action in human tumours for the prediction of drug responses. 2.) To modify the abnormal gene-expression underlying the malignant phenotype.

AB - Cancer chemotherapy represents a major area of oncology in Hungary, as the scientific contributions of the well trained and equipped research team are well known in many cancer centers abroad. The roots of the current research could be traced in the 1930s at the Internal Clinical Department of the Pázmány Peter University where the biological effects of mustard gas was investigated. The aims of these research were realized in 1950s at first in the National Institute of Oncology and later in other institutes as well. Consequently a multidisciplinary network of experimental cancer research involving pathologists, pharmacologists, biochemists, chemists and clinical doctors has been established in Hungary. Surveying the history of anticancer research with ample tradition makes possible to review the valuable achievements and to focus on experience to be utilized in the future. At the first stage of these studies the basic aim was to introduce new cytotoxic agents. One of these drugs, dibromomannitol is currently used in CML therapy and in the conditioning treatment before bone-marrow transplantation, whereas the other drug dibromodulcitol is under licensing for the treatment of brain tumours in USA. The introduction of updated pharmacokinetic and pharmacobiochemical research facilities had to be outlined in the second period of cancer chemotherapeutic studies as it was required by the drug development program. These new elements in cancer research allowed to elucidate the mode of actions of the cytostatic agents. Currently ongoing research differs in both conceptually and methodologically from the ones at previous periods. The aims of these studies concentrate on two tasks: 1.) To determine the pharmacobiochemical determinants of drugs action in human tumours for the prediction of drug responses. 2.) To modify the abnormal gene-expression underlying the malignant phenotype.

UR - http://www.scopus.com/inward/record.url?scp=84882648354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882648354&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84882648354

VL - 41

SP - 75

EP - 84

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -